Status:
COMPLETED
Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
Massachusetts General Hospital
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this clinical research study is to learn whether different ways of viewing echocardiogram pictures along with blood tests can help to see heart-related side effects of chemotherapy and tra...
Detailed Description
Echocardiogram: Because of the heart-related side effects of chemotherapy and trastuzumab, your regular doctor will monitor your heart's function as part of your routine care. You will have echocardi...
Eligibility Criteria
Inclusion
- Age 18 years or older
- HER-2 positive breast cancer
- Scheduled to receive Herceptin infusion therapy after exposure to anthracycline-based chemotherapy in one of the following manners: Adjuvant or neoadjuvant treatment with anthracycline-based chemotherapy preceded or followed by Herceptin infusion therapy, Herceptin monotherapy in patients with metastatic disease previously treated with anthracycline-based chemotherapy, Herceptin in combination with non-anthracycline chemotherapy in patients with metastatic disease previously treated with anthracycline-based chemotherapy
- Normal baseline left ventricular ejection fraction.
Exclusion
- Pre-existing cardiomyopathy (Left Ventricular Ejection Fraction (LVEF) \< 50%)
- Other contraindication to Herceptin therapy
Key Trial Info
Start Date :
November 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00806507
Start Date
November 1 2008
End Date
August 1 2011
Last Update
July 23 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Partners Healthcare Systems
Boston, Massachusetts, United States, 02199
2
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030